Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 84.70% | 123.07% | 116.13% | 83.87% | 119.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.12% | 171.81% | 94.62% | 116.45% | 136.92% |
| Operating Income | -62.12% | -171.81% | -94.62% | -116.45% | -136.92% |
| Income Before Tax | -60.34% | -194.03% | -67.04% | 23.48% | -104.18% |
| Income Tax Expenses | -- | 7,100.00% | 3,620.00% | -- | -- |
| Earnings from Continuing Operations | -60.64% | -194.58% | -68.46% | 23.48% | -104.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.64% | -194.58% | -68.46% | 23.48% | -104.18% |
| EBIT | -62.12% | -171.81% | -94.62% | -116.45% | -136.92% |
| EBITDA | -62.13% | -171.92% | -94.70% | -116.34% | -136.81% |
| EPS Basic | 97.36% | 96.43% | 98.05% | 95.81% | -24.36% |
| Normalized Basic EPS | 97.36% | 96.43% | 98.07% | 95.81% | -24.36% |
| EPS Diluted | 97.36% | 96.43% | 98.05% | 95.81% | -24.36% |
| Normalized Diluted EPS | 97.36% | 96.43% | 98.07% | 95.81% | -24.36% |
| Average Basic Shares Outstanding | 5,982.21% | 8,147.24% | 8,538.83% | 1,724.15% | 64.17% |
| Average Diluted Shares Outstanding | 5,982.21% | 8,147.24% | 8,538.83% | 1,724.15% | 64.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |